Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam Plus Aztreonam for MBL-producing Enterobacterales Bloodstream Infection
NCT05850871Unknown
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Irreversible Covalent Inhibitors, Inhalation Devices
- Countries
- 1
01
Overview
Open-label trial of ceftazidime + avibactam and aztreonam in Enterobacteriaceae infection (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoints: 30-day all-cause mortality, Clinical failure at day 14 and 1 more. Status: unknown.
02
Drugs
ceftazidime + avibactamaztreonam
03
Conditions
Enterobacteriaceae infection
Beyond the preview
Go deeper on NCT05850871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850871.